KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Shares Issued (2016 - 2021)

Halozyme Therapeutics (HALO) has disclosed Shares Issued for 12 consecutive years, with $4.3 million as the latest value for Q4 2021.

  • Quarterly Shares Issued fell 66.19% to $4.3 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $12.5 million through Dec 2021, down 80.22% year-over-year, with the annual reading at $14.0 million for FY2022, 12.08% up from the prior year.
  • Shares Issued for Q4 2021 was $4.3 million at Halozyme Therapeutics, down from $4.6 million in the prior quarter.
  • The five-year high for Shares Issued was $135.3 million in Q2 2017, with the low at -$602000.0 in Q1 2021.
  • Average Shares Issued over 5 years is $11.9 million, with a median of $4.2 million recorded in 2021.
  • The sharpest move saw Shares Issued tumbled 237.89% in 2017, then skyrocketed 206400.0% in 2018.
  • Over 5 years, Shares Issued stood at -$1000.0 in 2017, then surged by 206400.0% to $2.1 million in 2018, then skyrocketed by 294.13% to $8.1 million in 2019, then surged by 56.78% to $12.7 million in 2020, then crashed by 66.19% to $4.3 million in 2021.
  • According to Business Quant data, Shares Issued over the past three periods came in at $4.3 million, $4.6 million, and $4.2 million for Q4 2021, Q3 2021, and Q2 2021 respectively.